Seeking Alpha Market Currents 12/13/13
Advertising works on Twitter; RBC boosts price target
"A substantial 40% of Twitter (TWTR) advertisers reported improving ROI over the last six months and 40% have also increased their Twitter spend," says RBC Capital, upping its price target on Buy-rated Twitter to $60 from $33.
59% of respondents plan to increase ad spend with Twitter over the next twelve months.
Jay Yarow, provided by
Published 7:17 am, Friday, December 13, 2013
Here Are The Four Reasons Twitter's StockWill Continue Higher (TWTR)
1. Twitter is increasing its targeting on the platform, reaching Facebook levels of targeting accuracy. Twitter had a blog post explaining that it is going to be able to track usage from the web to the Twitter app and serve ads.
2. Twitter's ad exchange MoPub is going to sell ads outside of Twitter. This is a big expansion, and a big opportunity to generate revenue from more than just Twitter, which remains a relatively small service.
Before we move on to reasons 3 and 4, we should note that these previous two bits of news were made possible when the quiet period was lifted. Once Twitter was free to talk about its business publicly, it was able to provide clarity to investors.
3. RBC analyst Mark Mahaney jacked his price target to $60 this morning, the highest on the street. He was at $33 before, so this is a serious increase, and it's driving the stock today. In his note, Mahaney said, "We are increasing our estimates based on the positive results of our advertiser survey, our industry checks, and our increased conviction in Twitter’s advertiser tools and user functionality improvement potential."
4. There isn't a lot of Twitter stock out there to buy. Peck says Twitter didn't release a lot of stock in the firstplace, so there's a supply and demand issue. He says that a few shareholders have big chunks of the stock, but they're not selling, making it harder for people who want to buy.
Are You Overlooking A Big Opportunity?
By: Jamal Carnette
What did Twitter discover?
Twitter discovered it is more than just an advertiser. The real-time nature of Twitter makes it a data mining giant. Matter of fact, the company reported data licensing fees of $47 million during the nine months ended Sept. 30, equal to around 11% of total revenue during that period. Data licensing fees are fees Twitter receives from data partners to access, search, and analyze historical and real-time data on Twitter's platform. Right now, Twitter has five data partners that account for roughly 73% of its data licensing revenue and 8% of Twitter's overall revenue. However, the data appears to be valuable to these partners; licensing revenue was up 36% compared to 2012 with a 30% increase from existing partners.
In addition, the data mining nature and its data licensing business will allow Twitter to grow revenues directly and indirectly for more effective ads. Even the largest company in the world, Apple, has gotten in on this bandwagon by buying Topsy, a Twitter data miner, for millions. Quite simply, this data is inherently valuable.
Where I was wrongWe analyzed Twitter as if it were another Facebook, a mere ad-driven business with the majority of revenues from these ads -- that's currently the case, but that could also change. In fact, it has the potential to be a multi-revenue stream company more akin to LinkedIn than Facebook. If Twitter can grow its data licensing business like big data is growing (58% annualized growth between now and 2017, according to Wikibon), that business could eventually overtake its ad-driven revenue
charts shows it every time
The Fly on The Wall 11/17/13
Stock Market & Financial Investment News
December 17, 2013
TSLA Tesla starting to take pre-orders in China, CNBC reports
Tesla is starting to take pre-orders in China for the Model S and Model X, CNBC reports. CEO Elon Musksaid earlier this year that the company could eventually sell 10,000 Model S vehicles a year in Europe and 5,000 in Asia
Topeka Strong Buy on Twitter
The Street 12/17/13
"We see a well-defined ecosystem with strong network effects developing around Twitter Inc that shouldlead to out-sized shareholder returns for years to come," Anthony wrote in his note.
Biotech Stock Roundup:
by Arpita Dutt Published on December 18, 2013 |
CytRx showed highly positive top-line efficacy data from a phase IIb study. Results showed that patients with soft tissue sarcomas responded significantly better to treatment with CytRx’s aldoxorubicin compared to treatment with doxorubicin, a standard treatment for soft tissue sarcomas. This bodes well for the company and should increase interest in this candidate.
ARIAD Announces U.S. Resumption of Marketing and Commercial Distribution of Iclusig (ponatinib) in Refractory Philadelphia-Positive Leukemias
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
ARIAD Pharmaceuticals, Inc. (ARIA) today announced that the U.S. Food and Drug Administration (FDA) hasapproved revised U.S. Prescribing Information (USPI) and a Risk Evaluation and Mitigation Strategy (REMS) for Iclusig® (ponatinib) that allows immediate resumption of its marketing and commercial distribution
twtr many revenue steams